Can Tofacitinib be taken for a long time and its safety analysis report

Tofacitinib is an oral JAK inhibitor that regulates the immune system by inhibiting the Janus kinase signaling pathway and blocking the activity of inflammation-related cytokines. The drug has been widely used in the treatment of immune-related diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Due to its good efficacy in controlling chronic inflammation, many patients require long-term use to maintain stable disease, but this has also raised concerns about its long-term safety.

According to multiple international clinical studies, tofacitinib can sustainably control disease activity and improve patients' quality of life during long-term treatment. The results of the five-year follow-up study show that most patients can tolerate long-term use, and the disease recurrence rate is significantly reduced. In addition, patients can significantly reduce the dosage of hormones or other immunosuppressants while taking tofacitinib, reducing the risk of side effects associated with traditional drugs. These results support its feasibility as a long-term treatment for chronic diseases.

Although tofacitinib has clear efficacy, long-term use also has some potential risks. Studies have found that the drug may increase the risk of infections, especially shingles and lung infections. In addition, some patients are at increased risk of elevated blood lipids, elevated liver enzymes and cardiovascular events during long-term use, especially in patients over 60 years old, with a history of cardiovascular disease or smoking. There are also studies suggesting that long-term high-dose use may be associated with the risk of certain malignant tumors, and therefore must be closely monitored.

In order to reduce risks as much as possible while ensuring the efficacy, patients need to undergo regular examinations during the use of tofacitinib, including monitoring of liver function, blood lipids, blood routine and infection indicators. Doctors will also decide whether to continue using or adjust the dosage based on the patient's constitution, age and condition. For patients with high-risk factors, the benefits and risks should be weighed and alternative treatments used if necessary. Generally speaking, tofacitinib can be used for a long time under the guidance of professional doctors, but it must be combined with individualized evaluation and long-term follow-up to ensure safety and effectiveness.

Reference materials:https://www.xeljanz.com/